Two Thresholds, One Powerful Solution: A dd-cfDNA Webinar | Presented by Natera

Two Thresholds, One Powerful Solution: Combining the Quantity and Fraction of dd-cfDNA in a Single Blood Test to Improve the Accuracy of Noninvasive Rejection Screening Post Heart Transplantation | Presented by Natera

Wednesday, 25 September | 2:00 p.m. EDT / 18:00 UTC

Join ISHLT and Natera for a one-hour webinar where expert speakers will discuss recent developments with Prospera Heart tests. You’ll learn how these new tests significantly reduce the rate of false positives and improve the accuracy of detecting both acute cellular rejection and antibody mediated rejection after heart transplantation. 

REGISTER NOW 

Noninvasive monitoring for acute rejection with donor derived cell free DNA (dd-cfDNA)  is a proven alternative to invasive surveillance biopsies. Until recently, donor-derived cell-free DNA (dd-cfDNA) tests have only reported dd-cfDNA as a fraction of total cfDNA (dd-cfDNA %) in the circulation. This fraction can be confounded by fluctuations in the amount of total cfDNA, sometimes caused by factors unrelated to the health of the allograft, including infection, surgery, or chemotherapy. Prospera Heart now incorporates a second metric – the Donor Quantity Score (DQS) – which is the estimated quantity of cell-free DNA coming from the donated heart, and is independent of fluctuations in levels of total cell-free DNA.

Learn how the addition of DQS significantly reduces the rate of false positive results and improves the accuracy of detecting both acute cellular rejection (ACR) and antibody mediated rejection (AMR).